PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company that has come through a strong-growth screen with a solid technical setup rating, a combination that tries to identify stocks where both the business and the chart are turning up. The method behind the screen is straightforward: it starts with fundamental expansion, then requires a price pattern that suggests the market is starting to reward that expansion. In this case, the company’s growth metrics are strong, its balance sheet is unusually clean, and the chart has recently formed a tight consolidation near support.
How the strong growth and technical setup screen works
Strong-growth investing starts with the business. Revenue and earnings need to expand at a pace well above the broad market, and ideally with improving margins. But the screen that flagged this stock adds a second condition: the stock also needs a constructive technical setup, such as a pullback to support, a volatility contraction, or a breakout pattern near a defined resistance level.
The logic is that fundamentals tell you what to own, while the chart helps tell you when to act. A company can post excellent growth numbers and still trade sideways for months. By requiring both pieces, the screen tries to find stocks where the growth story is not just real, but also beginning to show up in price action.
Fundamental evidence: growth, health, and profitability
The company earns a ChartMill fundamental rating of 6 out of 10, with a growth rating of 8 out of 10 and a health rating of 8 out of 10. The profitability rating sits at 5 out of 10, which reflects some of the typical concerns around a clinical-stage biotech, but the underlying recent metrics are stronger than that headline score suggests.
Key figures from the fundamental report:
- Revenue grew 34.81% over the past year, while EPS grew 47.14%.
- Analysts expect EPS to grow 36.32% per year and revenue to grow 68.61% per year over the coming years.
- The company has no outstanding debt, a current ratio of 21.71, and an Altman-Z score of 132.20, placing its solvency well above most of its industry peers.
- Profitability ratios are strong on a relative basis: return on assets is 9.36%, return on equity is 9.85%, return on invested capital is 5.43%, and the operating margin is 20.69%.
- Valuation is mixed. The trailing P/E of 145.15 is high in absolute terms, but the stock is cheaper than roughly 90% of its industry peers on P/E, EV/EBITDA, and P/FCF.
The fundamental report describes the combination of excellent growth and a reasonable industry-relative valuation as an interesting setup for growth investors. That matters because the screen is not looking for the cheapest stock in the sector; it is looking for a business that can keep compounding while the market is still not demanding a premium that has already become extreme.
Investors who want to see all five sub-ratings in detail can pull up the full fundamental analysis report.
Technical evidence: an uptrend with a defined setup
The technical picture is where this stock becomes particularly interesting for the screen. ChartMill gives it a technical rating of 10 out of 10 and a setup rating of 8 out of 10. Both the short-term and long-term trends are positive, and the stock has shown a consistent pattern of higher prices over time.
Key technical observations:
- The stock is up 153.17% over the past 12 months, 50.16% over the past three months, and 62.36% over the past six months.
- Relative strength is 97.77, meaning the stock has outperformed roughly 97% of the market over the measured period.
- The 52-week range runs from 54.50 to 160.81, with the stock currently near 149.50.
- There is a support zone between 148.66 and 149.49, formed by a combination of trend lines and moving averages.
- The only important resistance area is at 158.63.
What makes the setup notable is that the stock has been consolidating after a strong advance. Volatility has contracted, and the price is pulling back toward support rather than breaking down. With very little overhead resistance above the current level, the pattern is the kind of coiling action that can precede a breakout attempt.
Traders and investors who want the full technical breakdown, including the support and resistance map, can view the technical analysis report.
Why this combination matters
Requiring both fundamental growth and a technical setup is not just a way to stack indicators. It is a risk filter. A strong business can spend a long time in a base before the market accepts its new earnings trajectory, and buying too early can tie up capital in a stock that goes nowhere. A chart that looks strong but has no revenue or earnings growth behind it can fail quickly when momentum fades.
By demanding both, the screen tries to find stocks where the trend in the business and the trend in the stock are pointing in the same direction. That does not guarantee a smooth path, but it does mean the candidate has passed two separate tests rather than just one.
Risks to weigh
There are also clear risks. The company is a clinical-stage biopharmaceutical business, so the fundamental picture can change quickly around clinical data, regulatory news, or financing decisions. It had negative earnings in four of the past five years and does not pay a dividend. The valuation is expensive in absolute terms, and if growth expectations reset, a high-multiple stock can correct sharply.
The fundamental report also notes that return on invested capital is currently below the cost of capital, which is typical for a company still investing ahead of commercialization. Share count has also increased slightly over the past year. For these reasons, the technical setup works best as part of a defined risk plan, not as a standalone buy signal.
Other screen confirmation
The same two-sided story also shows up in other ChartMill screens.
- On the fundamental side, PTGX is included in the fastest-growing stocks list, a screen built around strong earnings and sales growth plus overall business quality.
- On the technical side, PTGX appears in the breakout setups list, which targets strong uptrends, constructive consolidation, and enough volatility to support a potential breakout.
Together, these independent scans add confirmation that PTGX combines the growth profile and the chart setup the original screen is designed to capture.
Where to find more names using this approach
Investors who want to run this methodology for themselves can use this strong growth with technical setup screen to find more stocks that combine solid fundamental expansion with a constructive chart pattern. The screen updates as price action and fundamentals change, making it a useful starting point for a regular review process.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Protagonist Therapeutics (NASDAQ:PTGX) Combines Strong Growth with a Promising Technical Setup
PROTAGONIST THERAPEUTICS INC (NASDAQ:PTGX) is a clinical-stage biopharmaceutical company that has come through a strong-growth screen with a solid technical setup rating, a combination that tries to identify stocks where both the business and the chart are turning up. The method behind the screen is straightforward: it starts with fundamental expansion, then requires a price pattern that suggests the market is starting to reward that expansion. In this case, the company’s growth metrics are strong, its balance sheet is unusually clean, and the chart has recently formed a tight consolidation near support.
How the strong growth and technical setup screen works
Strong-growth investing starts with the business. Revenue and earnings need to expand at a pace well above the broad market, and ideally with improving margins. But the screen that flagged this stock adds a second condition: the stock also needs a constructive technical setup, such as a pullback to support, a volatility contraction, or a breakout pattern near a defined resistance level.
The logic is that fundamentals tell you what to own, while the chart helps tell you when to act. A company can post excellent growth numbers and still trade sideways for months. By requiring both pieces, the screen tries to find stocks where the growth story is not just real, but also beginning to show up in price action.
Fundamental evidence: growth, health, and profitability
The company earns a ChartMill fundamental rating of 6 out of 10, with a growth rating of 8 out of 10 and a health rating of 8 out of 10. The profitability rating sits at 5 out of 10, which reflects some of the typical concerns around a clinical-stage biotech, but the underlying recent metrics are stronger than that headline score suggests.
Key figures from the fundamental report:
The fundamental report describes the combination of excellent growth and a reasonable industry-relative valuation as an interesting setup for growth investors. That matters because the screen is not looking for the cheapest stock in the sector; it is looking for a business that can keep compounding while the market is still not demanding a premium that has already become extreme.
Investors who want to see all five sub-ratings in detail can pull up the full fundamental analysis report.
Technical evidence: an uptrend with a defined setup
The technical picture is where this stock becomes particularly interesting for the screen. ChartMill gives it a technical rating of 10 out of 10 and a setup rating of 8 out of 10. Both the short-term and long-term trends are positive, and the stock has shown a consistent pattern of higher prices over time.
Key technical observations:
What makes the setup notable is that the stock has been consolidating after a strong advance. Volatility has contracted, and the price is pulling back toward support rather than breaking down. With very little overhead resistance above the current level, the pattern is the kind of coiling action that can precede a breakout attempt.
Traders and investors who want the full technical breakdown, including the support and resistance map, can view the technical analysis report.
Why this combination matters
Requiring both fundamental growth and a technical setup is not just a way to stack indicators. It is a risk filter. A strong business can spend a long time in a base before the market accepts its new earnings trajectory, and buying too early can tie up capital in a stock that goes nowhere. A chart that looks strong but has no revenue or earnings growth behind it can fail quickly when momentum fades.
By demanding both, the screen tries to find stocks where the trend in the business and the trend in the stock are pointing in the same direction. That does not guarantee a smooth path, but it does mean the candidate has passed two separate tests rather than just one.
Risks to weigh
There are also clear risks. The company is a clinical-stage biopharmaceutical business, so the fundamental picture can change quickly around clinical data, regulatory news, or financing decisions. It had negative earnings in four of the past five years and does not pay a dividend. The valuation is expensive in absolute terms, and if growth expectations reset, a high-multiple stock can correct sharply.
The fundamental report also notes that return on invested capital is currently below the cost of capital, which is typical for a company still investing ahead of commercialization. Share count has also increased slightly over the past year. For these reasons, the technical setup works best as part of a defined risk plan, not as a standalone buy signal.
Other screen confirmation
The same two-sided story also shows up in other ChartMill screens.
Together, these independent scans add confirmation that PTGX combines the growth profile and the chart setup the original screen is designed to capture.
Where to find more names using this approach
Investors who want to run this methodology for themselves can use this strong growth with technical setup screen to find more stocks that combine solid fundamental expansion with a constructive chart pattern. The screen updates as price action and fundamentals change, making it a useful starting point for a regular review process.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »